Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

(2021) Hagop M. Kantarjian et al.   LEUKEMIA

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression

(2021) Richard E. Clark et al.   Blood Advances

MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response

(2021) Eman M Habib et al.   Labmedicine

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

(2021) Vaidehi Krishnan et al.   HAEMATOLOGICA

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML)

(2020) Ali G. Turhan et al.   LEUKEMIA & LYMPHOMA

The miR-185/PAK6 Axis Predicts Therapy Response and Regulates Survival of Drug-Resistant Leukemic Stem Cells in CML

(2020) Hanyang Lin et al.   BLOOD

Treatment-free remission in patients with chronic myeloid leukaemia

(2020) David M. Ross et al.   Nature Reviews Clinical Oncology

MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review

(2020) Wenxiu Xu et al.   CANCER SCIENCE

The role and mechanisms of action of microRNAs in cancer drug resistance

(2019) Wengong Si et al.   Clinical Epigenetics

MicroRNA signature refine response prediction in CML

(2019) Raquel Alves et al.   Scientific Reports

miR-145 supports cancer cell survival and shows association with DDR genes, methylation pattern, and epithelial to mesenchymal transition

(2019) Siddharth Manvati et al.   Cancer Cell International

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

(2019) Neil P. Shah et al.   LEUKEMIA & LYMPHOMA

BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia

(2018) Klara Srutova et al.   HAEMATOLOGICA

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison

(2018) Ingmar Glauche et al.   Scientific Reports

BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

(2018) Hye-young Song et al.   Cancer Medicine

Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation

(2018) Jacob O'Brien et al.   Frontiers in Endocrinology

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

(2017) Alice Giustacchini et al.   NATURE MEDICINE

miR-708-5p: a microRNA with emerging roles in cancer

(2017) Nicholas J. Monteleone et al.   Oncotarget

Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia

(2017) Alfonso Quintás-Cardama et al.   Cancer Control

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer

(2016) Alexander A. Svoronos et al.   CANCER RESEARCH

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia

(2016) Lauren Caldemeyer et al.   LEUKEMIA & LYMPHOMA

miRNAs in chronic myeloid leukemia: small molecules, essential function

(2016) Zofia Litwińska et al.   LEUKEMIA & LYMPHOMA

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

(2016) Sheela A. Abraham et al.   NATURE

MicroRNAs in Myeloid Hematological Malignancies

(2015) Maria Ciccone et al.   CURRENT GENOMICS

The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)

(2015) CARLA DI STEFANO et al.   ONCOLOGY REPORTS

ApoptomiRs expression modulated by BCR–ABL is linked to CML progression and imatinib resistance

(2014) A.F. Ferreira et al.   BLOOD CELLS MOLECULES AND DISEASES

Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options

(2013) Elias J. Jabbour et al.   Clinical Lymphoma Myeloma & Leukemia

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

MicroRNAs are shaping the hematopoietic landscape

(2011) U. Bissels et al.   HAEMATOLOGICA

Expression patterns of microRNAs associated with CML phases and their disease related targets

(2011) Kateřina Machová Poláková et al.   Molecular Cancer

Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate

(2010) X. Jiang et al.   BLOOD

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

(2010) S. Flamant et al.   HAEMATOLOGICA

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

(2009) Edurne San José-Enériz et al.   Molecular Cancer